Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.

Spear S, Candido JB, McDermott JR, Ghirelli C, Maniati E, Beers SA, Balkwill FR, Kocher HM, Capasso M.

Front Immunol. 2019 Mar 27;10:542. doi: 10.3389/fimmu.2019.00542. eCollection 2019.

2.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
3.

Mets and NETs: The Awakening Force.

Sanz-Moreno V, Balkwill FR.

Immunity. 2018 Nov 20;49(5):798-800. doi: 10.1016/j.immuni.2018.11.009.

PMID:
30462996
4.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

5.

Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, Montfort A, Dowe T, Gribben J, Jones JL, Kocher HM, Serody JS, Vincent BG, Connelly J, Brenton JD, Chelala C, Cutillas PR, Lockley M, Bessant C, Knight MM, Balkwill FR.

Cancer Discov. 2018 Mar;8(3):304-319. doi: 10.1158/2159-8290.CD-17-0284. Epub 2017 Dec 1.

6.

Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.

Naba A, Pearce OMT, Del Rosario A, Ma D, Ding H, Rajeeve V, Cutillas PR, Balkwill FR, Hynes RO.

J Proteome Res. 2017 Aug 4;16(8):3083-3091. doi: 10.1021/acs.jproteome.7b00191. Epub 2017 Jul 19.

PMID:
28675934
7.

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.

Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, Duncan AR, Fletcher L, Wilkinson RW, Powles T, Quezada SA, Balkwill FR.

J Clin Invest. 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. Epub 2017 Jan 30.

8.

CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden K, Lockley M, McNeish IA.

Cancer Res. 2016 Oct 15;76(20):6118-6129. Epub 2016 Aug 16.

9.

A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Montfort A, Pearce O, Maniati E, Vincent BG, Bixby L, Böhm S, Dowe T, Wilkes EH, Chakravarty P, Thompson R, Topping J, Cutillas PR, Lockley M, Serody JS, Capasso M, Balkwill FR.

Clin Cancer Res. 2017 Jan 1;23(1):250-262. doi: 10.1158/1078-0432.CCR-16-0081. Epub 2016 Jun 27.

10.

Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Montfort A, Pearce OM, Topping J, Chakravarty P, Everitt GL, Clear A, McDermott JR, Ennis D, Dowe T, Fitzpatrick A, Brockbank EC, Lawrence AC, Jeyarajah A, Faruqi AZ, McNeish IA, Singh N, Lockley M, Balkwill FR.

Clin Cancer Res. 2016 Jun 15;22(12):3025-36. doi: 10.1158/1078-0432.CCR-15-2657.

11.

Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.

Dawkins JB, Wang J, Maniati E, Heward JA, Koniali L, Kocher HM, Martin SA, Chelala C, Balkwill FR, Fitzgibbon J, Grose RP.

Cancer Res. 2016 Aug 15;76(16):4861-71. doi: 10.1158/0008-5472.CAN-16-0481. Epub 2016 Jun 8.

12.

Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanics.

Delaine-Smith RM, Burney S, Balkwill FR, Knight MM.

J Mech Behav Biomed Mater. 2016 Jul;60:401-415. doi: 10.1016/j.jmbbm.2016.02.019. Epub 2016 Feb 17.

13.

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells.

Kulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D, Braicu I, Sehouli J, Saez-Rodriguez J, Cutillas PR, Balkwill FR.

Oncotarget. 2016 Mar 29;7(13):15648-61. doi: 10.18632/oncotarget.7255.

14.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

15.

Inflammation and cancer: advances and new agents.

Crusz SM, Balkwill FR.

Nat Rev Clin Oncol. 2015 Oct;12(10):584-96. doi: 10.1038/nrclinonc.2015.105. Epub 2015 Jun 30. Review.

PMID:
26122183
16.

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR.

Cancer Res. 2015 Apr 1;75(7):1255-64. doi: 10.1158/0008-5472.CAN-14-1801. Epub 2015 Feb 10.

17.

Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.

Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ, Silva-Santos B.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3562-70. doi: 10.1073/pnas.1403424111. Epub 2014 Aug 11.

18.

Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.

Lau TS, Chung TK, Cheung TH, Chan LK, Cheung LW, Yim SF, Siu NS, Lo KW, Yu MM, Kulbe H, Balkwill FR, Kwong J.

J Pathol. 2014 Jan;232(1):43-56. doi: 10.1002/path.4258.

PMID:
24014111
19.

Vaccinia virus induces programmed necrosis in ovarian cancer cells.

Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D, McNeish IA.

Mol Ther. 2013 Nov;21(11):2074-86. doi: 10.1038/mt.2013.195. Epub 2013 Sep 24.

20.

Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.

Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T, Imhof BA, Balkwill FR, Nourshargh S.

FASEB J. 2013 Oct;27(10):4244-53. doi: 10.1096/fj.13-230441. Epub 2013 Jul 3.

21.

The tumor microenvironment at a glance.

Balkwill FR, Capasso M, Hagemann T.

J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6. doi: 10.1242/jcs.116392. No abstract available.

22.

The peritoneal tumour microenvironment of high-grade serous ovarian cancer.

Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S, Balkwill FR.

J Pathol. 2012 Jun;227(2):136-45. doi: 10.1002/path.4002. Epub 2012 Apr 18.

23.

Cancer-related inflammation: common themes and therapeutic opportunities.

Balkwill FR, Mantovani A.

Semin Cancer Biol. 2012 Feb;22(1):33-40. doi: 10.1016/j.semcancer.2011.12.005. Epub 2011 Dec 24. Review.

PMID:
22210179
24.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7.

25.

Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA, Hagemann T.

J Clin Invest. 2011 Dec;121(12):4685-99. doi: 10.1172/JCI45797. Epub 2011 Nov 7.

26.

The chemokine system and cancer.

Balkwill FR.

J Pathol. 2012 Jan;226(2):148-57. doi: 10.1002/path.3029. Epub 2011 Nov 23. Review.

PMID:
21989643
27.

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.

Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.

28.

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.

29.

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.

Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR.

Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7. doi: 10.1073/pnas.1100994108. Epub 2011 Jun 13.

30.

Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.

Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA.

Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.

31.

p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.

Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP, Balkwill FR, McNeish IA.

Mol Cancer. 2010 Jul 3;9:175. doi: 10.1186/1476-4598-9-175.

32.

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T.

J Clin Invest. 2009 Oct;119(10):3011-23. doi: 10.1172/JCI39065. Epub 2009 Sep 8.

33.

Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.

Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC.

Neoplasia. 2009 Jun;11(6):529-41.

34.

"Re-educating" tumor-associated macrophages by targeting NF-kappaB.

Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR.

J Exp Med. 2008 Jun 9;205(6):1261-8. doi: 10.1084/jem.20080108. Epub 2008 May 19.

35.

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF.

Ann Oncol. 2008 Jul;19(7):1340-6. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5.

PMID:
18325912
36.

IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ.

J Immunol. 2007 Sep 1;179(5):2832-43.

37.

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.

Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ.

Cancer Immunol Immunother. 2008 Feb;57(2):247-63. Epub 2007 Jul 27.

PMID:
17657488
38.

Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR.

Mol Cancer Ther. 2007 Jul;6(7):1993-2002.

39.

Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.

Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR.

Int J Cancer. 2007 Jul 1;121(1):6-11.

40.

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA.

Clin Cancer Res. 2006 Dec 1;12(23):7126-31.

41.

Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.

Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S, Balkwill FR.

J Immunol. 2006 Apr 15;176(8):5023-32.

42.

10th Biennial Helene Harris Memorial Trust meeting.

Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND.

Cancer Res. 2006 Mar 15;66(6):2904-6.

43.

Tumour necrosis factor-alpha as a tumour promoter.

Szlosarek P, Charles KA, Balkwill FR.

Eur J Cancer. 2006 Apr;42(6):745-50. Epub 2006 Mar 6. Review.

PMID:
16517151
44.

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.

Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR.

Mol Cancer Ther. 2006 Feb;5(2):382-90.

45.

The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL.

Cancer Res. 2005 Nov 15;65(22):10355-62.

46.

Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.

Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR.

J Immunol. 2005 Jul 15;175(2):1197-205.

47.

TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?

Scott KA, Arnott CH, Robinson SC, Moore RJ, Thompson RG, Marshall JF, Balkwill FR.

Oncogene. 2004 Sep 9;23(41):6954-66.

PMID:
15273742
48.

A role for endothelin-2 and its receptors in breast tumor cell invasion.

Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR.

Cancer Res. 2004 Apr 1;64(7):2461-8.

49.

Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.

Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C.

Carcinogenesis. 2004 Aug;25(8):1543-9. Epub 2004 Mar 25.

PMID:
15044327
50.

A chemokine receptor antagonist inhibits experimental breast tumor growth.

Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR.

Cancer Res. 2003 Dec 1;63(23):8360-5.

Supplemental Content

Loading ...
Support Center